<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">YM</journal-id><journal-title-group><journal-title>Yangtze Medicine</journal-title></journal-title-group><issn pub-type="epub">2475-7330</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ym.2023.71001</article-id><article-id pub-id-type="publisher-id">YM-123558</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  NLRP3 Inflammasome in Relation to Glucose and Lipid Metabolism, and Insulin Resistance in Diabetes and Pre-Diabetes
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Shujuan</surname><given-names>Hu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Dang</surname><given-names>Liu</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yinqi</surname><given-names>Zhang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Yiting</surname><given-names>Ding</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Bingqing</surname><given-names>Li</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Xianwang</surname><given-names>Wang</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Clinical Laboratory, The Second School of Clinical Medicine and Jingzhou Central Hospital, Yangtze University, Jingzhou, China</addr-line></aff><aff id="aff2"><addr-line>Department of Biochemistry and Molecular Biology, Center for Molecular Medicine, Health Science Center, Yangtze University, Jingzhou, China</addr-line></aff><aff id="aff1"><addr-line>School of Education and Physical Education, Yangtze University, Jingzhou, China</addr-line></aff><pub-date pub-type="epub"><day>08</day><month>03</month><year>2023</year></pub-date><volume>07</volume><issue>01</issue><fpage>1</fpage><lpage>10</lpage><history><date date-type="received"><day>4,</day>	<month>January</month>	<year>2023</year></date><date date-type="rev-recd"><day>6,</day>	<month>March</month>	<year>2023</year>	</date><date date-type="accepted"><day>9,</day>	<month>March</month>	<year>2023</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Aims: To investigate the relationship among NLRP3 inflammasome, glucose and lipid metabolism, and insulin resistance (IR) in the serum of patients with diabetes and pre-diabetes. 
  Methods: A total of 100 patients with abnormal blood glucose divided into the pre-diabetes mellitus (PDM) group (N = 46) and the type 2 diabetes mellitus (T2DM) group (N = 54). 20 normoglycemic subjects (NG, N = 20) were selected as a control group. The serum levels of glucose and lipid metabolism, IR, and the expression of NLRP3, ASC and Caspase-1 were measured. Besides, the correlations of NLRP3 inflammasome with glucose and lipid metabolism, and IR were analyzed. 
  Results: Compared with the NG group, the levels of NLRP3, ASC, Caspase-1, FBG, HbA
  <sub>1</sub>C, TG, LDL-C, FINs, and HOMA-IR were higher (
  <em>P</em> &lt; 0.05), while the contents of HDL-C and HOMA-
  <em>β</em> were lower (
  <em>P</em> &lt; 0.05) in the serum of both PDM and T2DM groups. Elevated levels of NLRP3, ASC, Caspase-1, FBG, HbA
  <sub>1</sub>C, FINs, and HOMA-IR were detected (
  <em>P</em> &lt; 0.05), while decreased contents of HDL-C and HOMA-
  <em>β</em> were seen (
  <em>P</em> &lt; 0.05) in T2DM group when compared with those in the PDM group. Correlation analysis found that activation of NLRP3 inflammasome was positively correlated with the concentrations of HbA
  <sub>1</sub>C, FINs, and HOMA-IR (
  <em>P</em> &lt; 0.05), but negatively correlated with HDL-C and HOMA-
  <em>β</em>. Regression analysis further showed that blood glucose related indexes, FINs, and NLRP3 have made a decisive contribution to IR. 
  Conclusions: Collectively, this evidence suggested that NLRP3 is closely related to glucose and lipid metabolism, and IR, and activated in PDM and T2DM.
 
</p></abstract><kwd-group><kwd>Type 2 Diabetes Mellitus</kwd><kwd> Pre-Diabetes Mellitus</kwd><kwd> NLRP3</kwd><kwd> Glucose and Lipid Metabolism</kwd><kwd> Insulin Resistance</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>According to the diabetes map released by the International Diabetes Federation in 2019, there are nearly 500 million diabetes patients in the world, and it is estimated that there will be 629 million diabetes patients in 2045 [<xref ref-type="bibr" rid="scirp.123558-ref1">1</xref>] , more than 90% of them are type 2 diabetes mellitus (T2DM). Pre-diabetes mellitus (PDM) is a state in which blood glucose concentrations are between normal and diabetic hyperglycemia [<xref ref-type="bibr" rid="scirp.123558-ref2">2</xref>] . The prevalence of PDM in adults is 35.7%, and it is increasing year by year [<xref ref-type="bibr" rid="scirp.123558-ref2">2</xref>] . Due to the complex pathogenesis of diabetes, it is characterized that chronic inflammation and insulin resistance (IR) are pivotal factors for the occurrence and development of diabetes [<xref ref-type="bibr" rid="scirp.123558-ref3">3</xref>] . The roles of inflammasome and its related factors in diabetes and IR have attracted much attention, and have become important targets for the prevention and treatment of metabolic diseases [<xref ref-type="bibr" rid="scirp.123558-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.123558-ref5">5</xref>] .</p><p>Nod-like receptor protein 3 (NLRP3) inflammasome is a multi-protein complex composed of the core member (NLRP3), apoptosis-associated spot-like protein (ASC), and Caspase-1 [<xref ref-type="bibr" rid="scirp.123558-ref6">6</xref>] [<xref ref-type="bibr" rid="scirp.123558-ref7">7</xref>] . Chronic inflammatory responses mediated by NLRP3 inflammasome and related factors play an important role in the progression of diabetes [<xref ref-type="bibr" rid="scirp.123558-ref5">5</xref>] . It was found that the levels of NLRP3 and Caspase-1 in the serum of diabetic patients were significantly increased, and correlated with the progression of diabetes [<xref ref-type="bibr" rid="scirp.123558-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.123558-ref9">9</xref>] . However, the activation of NLRP3 inflammasome in PDM patients, and the correlation among NLRP3 inflammasome, glucose and lipid metabolism, and IR remain unexplored. The aim of this study was to address the activation of NLRP3 inflammasome in both T2DM and PDM patients, and to analyze the relationship among NLRP3 inflammasome, glucose and lipid metabolism, and IR, thereby providing an important clue for the clinical prevention and alleviation of metabolic related diseases.</p></sec><sec id="s2"><title>2. Materials and Methods</title><sec id="s2_1"><title>2.1. General Information</title><p>A total of 100 patients with abnormal blood glucose in the Second School of Clinical Medicine and Jingzhou Central Hospital of Yangtze University from April to August 2022 were selected. According to the Guidelines for the Diagnosis and Treatment of Diabetes issued by the American Diabetes Association (ADA) in 2019 [<xref ref-type="bibr" rid="scirp.123558-ref10">10</xref>] , the patients were divided into the PDM group (N = 46) and the T2DM group (N = 54). There were 16 males and 38 females in the PDM group with an age of (60.63 &#177; 6.44) years. There were 26 males and 20 females in the T2DM group with an age of (60.22 &#177; 6.07) years, and the disease duration was (7.09 &#177; 2.98) years. At the same time, 20 normoglycemic subjects (NG group) in the outpatient department of the hospital were selected as a control group. There were 10 males and 10 females in the NG group with an age of (58.50 &#177; 5.41) years. There was no significant difference in age among the groups (P &gt; 0.05). The study was approved by the ethics committee of the Health Science Center of Yangtze University (approval number: YZLL2022-006).</p></sec><sec id="s2_2"><title>2.2. Inclusion and Exclusion Criteria</title><p>Inclusion criteria: T2DM patients (N = 54), 1) Subjects with fasting blood glucose (FBG) &gt; 125 mg/dL or plasma glucose after 2 hours (2 hPG) &gt; 199 mg/dL. 2) Blood glucose ≥ 199 mg/dL at any time. 3) Age: 50 - 70 years old. PDM patients (N = 46), a) Subjects with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), defined as FBG 100 - 125 mg/dL or 2 hPG 140 - 199 mg/dL. b) Age: 50 - 70 years old. NG group (N = 20), i) Subjects with normal fasting glucose and normal glucose tolerance, defined as FBG &lt; 100 mg/dL and 2 hPG &lt; 140 mg/dL. ii) Age: 50 - 70 years old.</p><p>Exclusion criteria: Patients with type 1 diabetes mellitus, other special types of diabetes mellitus, abnormal liver and kidney function, tumor history and other serious diseases were excluded.</p></sec><sec id="s2_3"><title>2.3. The Research Methods</title><p>Blood samples were collected from all subjects. Fasting for more than 8 hours was required. 5 ml of venous blood was extracted on an empty stomach in the next morning and centrifuged at 1000 r/min for 20 min with a radius of 12.8 cm, and 2 ml serum was collected. Serum levels of NLRP3, ASC and Caspase-1 were detected by an enzyme-linked immunosorbent assay (ELISA) kit (Sin-Troch, China). The operation was completed according to the kit instructions. The biochemical indexes including fasting insulin (FINs), total cholesterol (TC), triglyceride (TG), low-density cholesterol (LDL-C), high-density cholesterol (HDL-C) were measured with Hitachi 7600 automatic biochemical analyzer. FBG was measured by a Roche blood glucose meter. In addition, Hitachi 7170A automatic glycosylated hemoglobin analyzer was used to determine glycosylated hemoglobin (HbA<sub>l</sub>C). To evaluate IR, the homeostatic model assessment for IR was calculated: HOMA-IR = (FBG &#215; FINs)/22.5. To evaluate beta cell function, the homeostatic model assessment of beta cell function was calculated: HOMA-β = 20 &#215; FINs/(FBG-3.5) [<xref ref-type="bibr" rid="scirp.123558-ref11">11</xref>] .</p></sec><sec id="s2_4"><title>2.4. Statistical Analysis</title><p>SPSS23.0 statistical software was used to process the measured data, and the experimental data were expressed as the mean &#177; standard deviation ( x &#177; s ). Comparison among the three groups was performed by one-way ANOVA, and the LSD-T test was used for pairwise comparison between groups. Pearson method was used for correlation analysis, and linear regression was used for regression analysis. P &lt; 0.05 or P &lt; 0.01 means the difference is statistically significant.</p></sec></sec><sec id="s3"><title>3. Results</title><sec id="s3_1"><title>3.1. Clinical Data and Biochemical Indexes Analysis</title><p>One-way ANOVA was applied to analyze the related indexes of glucose and lipid metabolism, and IR in the NG, PDM and T2DM groups. As shown in <xref ref-type="table" rid="table1">Table 1</xref>, the results demonstrated that statistically significant differences in FBG, HbA<sub>1</sub>C, TG, HDL-C, LDL-C, FINs, HOMA-IR, and HOMA-β (P &lt; 0.05). Compared with the NG group, the levels of HbA<sub>1</sub>C, TG, LDL-C, FINs, and HOMA-IR were higher (P &lt; 0.05), HDL-C and HOMA-β were lower (P &lt; 0.05) in the serum of either PDM or T2DM groups. Moreover, the contents of FBG, HbA<sub>1</sub>C, FINs, and HOMA-IR were increased (P &lt; 0.05), HDL-C and HOMA-β were decreased (P &lt; 0.05) in the serum of the T2DM group when compared with those in the PDM group.</p></sec><sec id="s3_2"><title>3.2. Activation of NLRP3 Inflammasome in the Patients with PDM and T2DM</title><p>To detect the expression of NLRP3 inflammasome in the serum of the NG, PDM and T2DM groups, ELISA assay was implemented. As shown in <xref ref-type="table" rid="table2">Table 2</xref>, the relative expression levels of NLRP3 in the NG, PDM and T2DM groups were (387.64 &#177; 34.87), (779.91 &#177; 124.63) and (841.04 &#177; 81.76), respectively. The expression levels of ASC were (327.21 &#177; 45.00), (651.64 &#177; 117.40) and (726.00 &#177; 79.95) in the NG, PDM and T2DM groups, separately. The Caspase-1 expression</p><table-wrap-group id="1"><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical data and biochemical indexes</title></caption><table-wrap id="1_1"><table><tbody><thead><tr><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >FBG (mmol/L)</th><th align="center" valign="middle" >HbA<sub>1</sub>C (%)</th><th align="center" valign="middle" >TG (mmol/L)</th><th align="center" valign="middle" >TC (mmol/L)</th><th align="center" valign="middle" >HDL-C (mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >T2DM</td><td align="center" valign="middle" >9.64 &#177; 3.27<sup>a,b</sup></td><td align="center" valign="middle" >8.70 &#177; 1.28<sup>a,b</sup></td><td align="center" valign="middle" >2.68 &#177; 1.73<sup>a</sup></td><td align="center" valign="middle" >5.09 &#177; 0.92</td><td align="center" valign="middle" >1.27 &#177; 0.26<sup>a,b</sup></td></tr><tr><td align="center" valign="middle" >PDM</td><td align="center" valign="middle" >6.40 &#177; 0.28</td><td align="center" valign="middle" >6.17 &#177; 0.32<sup>a</sup></td><td align="center" valign="middle" >2.20 &#177; 1.23<sup>a</sup></td><td align="center" valign="middle" >5.18 &#177; 1.02<sup>a</sup></td><td align="center" valign="middle" >1.80 &#177; 0.58<sup>a</sup></td></tr><tr><td align="center" valign="middle" >NG</td><td align="center" valign="middle" >5.52 &#177; 0.34</td><td align="center" valign="middle" >5.59 &#177; 0.28</td><td align="center" valign="middle" >1.18 &#177; 0.27</td><td align="center" valign="middle" >4.66 &#177; 1.00</td><td align="center" valign="middle" >2.05 &#177; 0.39</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.126</td><td align="center" valign="middle" >0.000**</td></tr></tbody></table></table-wrap><table-wrap id="1_2"><table><tbody><thead><tr><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >LDL-C (mmol/L)</th><th align="center" valign="middle" >FINs (μU/mL)</th><th align="center" valign="middle" >HOMA-IR</th><th align="center" valign="middle" >HOMA-β</th></tr></thead><tr><td align="center" valign="middle" >T2DM</td><td align="center" valign="middle" >3.49 &#177; 0.73<sup>a</sup></td><td align="center" valign="middle" >11.46 &#177; 2.23<sup>a,b</sup></td><td align="center" valign="middle" >4.94 &#177; 2.11<sup>a,b</sup></td><td align="center" valign="middle" >46.02 &#177; 20.93<sup>a,b</sup></td></tr><tr><td align="center" valign="middle" >PDM</td><td align="center" valign="middle" >3.33 &#177; 0.67<sup>a</sup></td><td align="center" valign="middle" >10.40 &#177; 2.28<sup>a</sup></td><td align="center" valign="middle" >2.96 &#177; 0.68<sup>a</sup></td><td align="center" valign="middle" >72.12 &#177; 16.04</td></tr><tr><td align="center" valign="middle" >NG</td><td align="center" valign="middle" >2.72 &#177; 0.68</td><td align="center" valign="middle" >7.15 &#177; 1.36</td><td align="center" valign="middle" >1.76 &#177; 0.37</td><td align="center" valign="middle" >73.27 &#177; 20.90</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td></tr></tbody></table></table-wrap></table-wrap-group><p>Note: **P &lt; 0.01, *P &lt; 0.05. <sup>a</sup>P &lt; 0.05 vs. NG group; <sup>b</sup>P &lt; 0.05 vs. PDM group.</p><p>were (37.39 &#177; 2.74), (67.32 &#177; 14.82) and (75.02 &#177; 8.12) in the NG, PDM and T2DM groups, respectively. Analysis of variance found that the differences were statistically significant among the NG, PDM and T2DM groups (P = 0.000). Compared with the NG group, the relative expression levels of NLRP3, ASC and Caspase-1 were higher in the PDM and T2DM groups (P &lt; 0.01). The relative expression levels of NLRP3, ASC and Caspase-1 in the serum of the T2DM group were higher (P &lt; 0.05) when compared with those the PDM group.</p></sec><sec id="s3_3"><title>3.3. NLRP3 Inflammasome Is Closely Related to Glucose and Lipid Metabolism, IR</title><p>Correlation analysis is applied to address the relationship among the expression level of NLRP3 inflammasome, glucose and lipid metabolism, and IR. As shown in <xref ref-type="table" rid="table3">Table 3</xref>, the expression level of NLRP3 in the serum was positively correlated with ASC, Caspase-1, FBG, HbA<sub>1</sub>C, FINs, and HOMA-IR (P &lt; 0.01), and was negatively correlated with HDL-C and HOMA-β (P &lt; 0.01). No significant correlation was detected between NLRP3 inflammasome with TC. The expression level of ASC was closely related to NLRP3, Caspase-1, FBG, HbA<sub>1</sub>C, TG, LDL-C, FINs, and HOMA-IR (P &lt; 0.01), especially positively correlated with NLRP3, Caspase-1, HbA<sub>1</sub>C, FINs and HOMA-IR, and negatively correlated with HDL-C</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> The expression levels of NLRP3 inflammasome in the serum of the NG, PDM and T2DM groups</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Group</th><th align="center" valign="middle" >NLRP3 (pm/ml)</th><th align="center" valign="middle" >ASC (pm/ml)</th><th align="center" valign="middle" >Caspase-1 (pm/ml)</th></tr></thead><tr><td align="center" valign="middle" >T2DM</td><td align="center" valign="middle" >841.04 &#177; 81.76<sup>a,b</sup></td><td align="center" valign="middle" >726.00 &#177; 79.95<sup>a,b</sup></td><td align="center" valign="middle" >75.02 &#177; 8.12<sup>a,b</sup></td></tr><tr><td align="center" valign="middle" >PDM</td><td align="center" valign="middle" >779.91 &#177; 124.6<sup>a</sup></td><td align="center" valign="middle" >651.64 &#177; 117.40<sup>a</sup></td><td align="center" valign="middle" >67.32 &#177; 14.82<sup>a</sup></td></tr><tr><td align="center" valign="middle" >NG</td><td align="center" valign="middle" >387.64 &#177; 34.87</td><td align="center" valign="middle" >327.21 &#177; 45.00</td><td align="center" valign="middle" >37.39 &#177; 2.74</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td></tr></tbody></table></table-wrap><p>Note: **P &lt; 0.01, *P &lt; 0.05. <sup>a</sup>P &lt; 0.05 vs. NG group; <sup>b</sup>P &lt; 0.05 vs. PDM group.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation among NLRP3 with inflammasome, glucose and lipid metabolism, and IR</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >NLRP3</th><th align="center" valign="middle" >ASC</th><th align="center" valign="middle" >Caspase-1</th><th align="center" valign="middle" >FBG</th><th align="center" valign="middle" >HbA<sub>1</sub>C</th><th align="center" valign="middle" >TC</th><th align="center" valign="middle" >TG</th><th align="center" valign="middle" >HDL-C</th><th align="center" valign="middle" >LDL-C</th><th align="center" valign="middle" >FINs</th><th align="center" valign="middle" >HOMA-IR</th><th align="center" valign="middle" >HOMA-β</th></tr></thead><tr><td align="center" valign="middle" >r</td><td align="center" valign="middle" >0.701</td><td align="center" valign="middle" >0.700</td><td align="center" valign="middle" >0.337</td><td align="center" valign="middle" >0.473</td><td align="center" valign="middle" >0.107</td><td align="center" valign="middle" >0.222</td><td align="center" valign="middle" >−0.412</td><td align="center" valign="middle" >0.211</td><td align="center" valign="middle" >0.473</td><td align="center" valign="middle" >0.410</td><td align="center" valign="middle" >−0.266</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.245</td><td align="center" valign="middle" >0.015*</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.021*</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.003**</td></tr><tr><td align="center" valign="middle" >ASC</td><td align="center" valign="middle" >NLRP3</td><td align="center" valign="middle" >Caspase-1</td><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >HbA1C</td><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >FINs</td><td align="center" valign="middle" >HOMA-IR</td><td align="center" valign="middle" >HOMA-β</td></tr><tr><td align="center" valign="middle" >r</td><td align="center" valign="middle" >0.701</td><td align="center" valign="middle" >0.609</td><td align="center" valign="middle" >0.380</td><td align="center" valign="middle" >0.511</td><td align="center" valign="middle" >0.264</td><td align="center" valign="middle" >0.288</td><td align="center" valign="middle" >−0.303</td><td align="center" valign="middle" >0.254</td><td align="center" valign="middle" >0.473</td><td align="center" valign="middle" >0.452</td><td align="center" valign="middle" >−0.266</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.004**</td><td align="center" valign="middle" >0.001**</td><td align="center" valign="middle" >0.001**</td><td align="center" valign="middle" >0.005**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.003**</td></tr><tr><td align="center" valign="middle" >Caspase-1</td><td align="center" valign="middle" >NLRP3</td><td align="center" valign="middle" >ASC</td><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >HbA1C</td><td align="center" valign="middle" >TC</td><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >FINs</td><td align="center" valign="middle" >HOMA-IR</td><td align="center" valign="middle" >HOMA-β</td></tr><tr><td align="center" valign="middle" >r</td><td align="center" valign="middle" >0.700</td><td align="center" valign="middle" >0.609</td><td align="center" valign="middle" >0.329</td><td align="center" valign="middle" >0.481</td><td align="center" valign="middle" >0.122</td><td align="center" valign="middle" >0.206</td><td align="center" valign="middle" >−0.503</td><td align="center" valign="middle" >0.246</td><td align="center" valign="middle" >0.484</td><td align="center" valign="middle" >0.415</td><td align="center" valign="middle" >−0.209</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.186</td><td align="center" valign="middle" >0.024*</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.007**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.022*</td></tr></tbody></table></table-wrap><p>Note: **P &lt; 0.01,*P &lt; 0.05.</p><p>and HOMA-β (P &lt; 0.01). The expression level of Caspase-1 was positively correlation with NLRP3, ASC, HbA<sub>1</sub>C, FINs, and HOMA-IR (0.4 &lt; r &lt; 0.7), and negatively correlated with HDL-C and HOMA-β (P &lt; 0.05). To sum up, NLRP3 inflammasome was positively correlated with HbA<sub>1</sub>C, FINs, HOMA-IR, and negatively correlated with HDL-C and HOMA-β.</p></sec><sec id="s3_4"><title>3.4. NLRP3 Act as an Important Affecting Factor for IR</title><p>To estimate the contribution of NLRP3 to IR, the linear regression analysis was applied. HOMA-IR and HOMA-β are commonly thought to be the representatives for IR [<xref ref-type="bibr" rid="scirp.123558-ref11">11</xref>] . As shown in <xref ref-type="table" rid="table4">Table 4</xref>, HOMA-IR was performed as the dependent variable, and FBG, HbA<sub>1</sub>C, TG, HDL-C, LDL-C, FINs, HOMA-β, NLRP3, ASC, and Caspase-1 were used as the independent variables. The results indicated that FBG, FINs, and NLRP3 were important factors influencing HOMA-IR. Furtherly, linear regression analysis was performed with HOMA-β as the dependent variable, FBG, HbA<sub>1</sub>C, TG, HDL-C, LDL-C, FINs, HOMA-IR, NLRP3, ASC, and Caspase-1 as the independent variables. We found that HbA<sub>1</sub>C, FINs, and NLRP3 are crucial factors for HOMA-β (<xref ref-type="table" rid="table5">Table 5</xref>). Taken together, these results suggested that FBG, HbA<sub>1</sub>C, FINs, and NLRP3 are vital factors for IR. Especially, NLRP3 is a key affecting factor for IR.</p></sec></sec><sec id="s4"><title>4. Discussion</title><p>IR and chronic inflammation are the main causes for the development of T2DM [<xref ref-type="bibr" rid="scirp.123558-ref12">12</xref>] . T2DM is closely related to abnormal glucose and lipid metabolism, IR, and islet function [<xref ref-type="bibr" rid="scirp.123558-ref13">13</xref>] . The results of this study confirmed that the contents of HbA<sub>1</sub>C, TG, LDL-C, FINs, and HOMA-IR were enhanced, while HDL-C and HOMA-β were decreased in the serum of patients with PDM and T2DM, further suggesting that the abnormal levels of them is related to the occurrence of</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Regression analysis of HOMA-IR</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Factor</th><th align="center" valign="middle" >β</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >95%CI</th></tr></thead><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >0.521</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >25.929</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.481 - 0.561</td></tr><tr><td align="center" valign="middle" >HbA<sub>1</sub>C</td><td align="center" valign="middle" >−0.029</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >−1.149</td><td align="center" valign="middle" >0.253</td><td align="center" valign="middle" >−0.079 - 0.021</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >0.009</td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" >0.480</td><td align="center" valign="middle" >0.632</td><td align="center" valign="middle" >−0.028 - 0.046</td></tr><tr><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >0.055</td><td align="center" valign="middle" >0.309</td><td align="center" valign="middle" >0.758</td><td align="center" valign="middle" >−0.092 - 0.126</td></tr><tr><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >−0.003</td><td align="center" valign="middle" >0.035</td><td align="center" valign="middle" >−0.077</td><td align="center" valign="middle" >0.939</td><td align="center" valign="middle" >−0.071 - 0.066</td></tr><tr><td align="center" valign="middle" >FINs</td><td align="center" valign="middle" >0.350</td><td align="center" valign="middle" >0.018</td><td align="center" valign="middle" >19.446</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >0.314 - 0.385</td></tr><tr><td align="center" valign="middle" >HOMA-β</td><td align="center" valign="middle" >−0.003</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >−1.129</td><td align="center" valign="middle" >0.262</td><td align="center" valign="middle" >−0.008 - 0.002</td></tr><tr><td align="center" valign="middle" >NLRP3</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−2.068</td><td align="center" valign="middle" >0.041*</td><td align="center" valign="middle" >−0.001 - 0.000</td></tr><tr><td align="center" valign="middle" >ASC</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >0.000</td><td align="center" valign="middle" >−1.028</td><td align="center" valign="middle" >0.306</td><td align="center" valign="middle" >−0.001 - 0.000</td></tr><tr><td align="center" valign="middle" >Caspase-1</td><td align="center" valign="middle" >−0.002</td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >−1.090</td><td align="center" valign="middle" >0.278</td><td align="center" valign="middle" >−0.007 - 0.002</td></tr></tbody></table></table-wrap><p>Note: **P &lt; 0.01,*P &lt; 0.05.</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Regression analysis of HOMA-β</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Factor</th><th align="center" valign="middle" >β</th><th align="center" valign="middle" >SE</th><th align="center" valign="middle" >t</th><th align="center" valign="middle" >P</th><th align="center" valign="middle" >95%CI</th></tr></thead><tr><td align="center" valign="middle" >FBG</td><td align="center" valign="middle" >−3.978</td><td align="center" valign="middle" >2.015</td><td align="center" valign="middle" >−1.975</td><td align="center" valign="middle" >0.051</td><td align="center" valign="middle" >−7.972 - 0.015</td></tr><tr><td align="center" valign="middle" >HbA<sub>1</sub>C</td><td align="center" valign="middle" >−2.751</td><td align="center" valign="middle" >0.935</td><td align="center" valign="middle" >−2.943</td><td align="center" valign="middle" >0.004**</td><td align="center" valign="middle" >−4.604 - −0.898</td></tr><tr><td align="center" valign="middle" >TG</td><td align="center" valign="middle" >−0.049</td><td align="center" valign="middle" >0.706</td><td align="center" valign="middle" >−0.070</td><td align="center" valign="middle" >0.944</td><td align="center" valign="middle" >−1.449 - 1.350</td></tr><tr><td align="center" valign="middle" >HDL-C</td><td align="center" valign="middle" >−0.804</td><td align="center" valign="middle" >2.091</td><td align="center" valign="middle" >−0.384</td><td align="center" valign="middle" >0.701</td><td align="center" valign="middle" >−4.947 - 3.340</td></tr><tr><td align="center" valign="middle" >LDL-C</td><td align="center" valign="middle" >0.119</td><td align="center" valign="middle" >1.316</td><td align="center" valign="middle" >0.090</td><td align="center" valign="middle" >0.928</td><td align="center" valign="middle" >−2.489 - 2.726</td></tr><tr><td align="center" valign="middle" >FINs</td><td align="center" valign="middle" >7.017</td><td align="center" valign="middle" >1.283</td><td align="center" valign="middle" >5.468</td><td align="center" valign="middle" >0.000**</td><td align="center" valign="middle" >4.474 - 9.561</td></tr><tr><td align="center" valign="middle" >HOMA-IR</td><td align="center" valign="middle" >−4.095</td><td align="center" valign="middle" >3.628</td><td align="center" valign="middle" >−1.129</td><td align="center" valign="middle" >0.262</td><td align="center" valign="middle" >−11.286 - 3.096</td></tr><tr><td align="center" valign="middle" >NLRP3</td><td align="center" valign="middle" >−0.023</td><td align="center" valign="middle" >0.008</td><td align="center" valign="middle" >−2.930</td><td align="center" valign="middle" >0.004**</td><td align="center" valign="middle" >−0.039 - −0.007</td></tr><tr><td align="center" valign="middle" >ASC</td><td align="center" valign="middle" >−0.008</td><td align="center" valign="middle" >0.008</td><td align="center" valign="middle" >−0.984</td><td align="center" valign="middle" >0.327</td><td align="center" valign="middle" >−0.024 - 0.008</td></tr><tr><td align="center" valign="middle" >Caspase-1</td><td align="center" valign="middle" >−0.071</td><td align="center" valign="middle" >0.083</td><td align="center" valign="middle" >−0.862</td><td align="center" valign="middle" >0.390</td><td align="center" valign="middle" >−0.235 - 0.092</td></tr></tbody></table></table-wrap><p>Note: **P &lt; 0.01, *P &lt; 0.05.</p><p>T2DM. In addition, FBG, HbA<sub>1</sub>C, FINs, and HOMA-IR were increased, and HDL-C, HOMA-β were lower in the serum of the T2DM group when compared with those in the PDM group, indicating that the development of diabetes may be closely related to glucose and lipid metabolism, and IR.</p><p>The NLRP3 inflammasome is a multiprotein complex responsible for the activation of inflammatory responses and plays an important role in the development of innate immunity and inflammation-related diseases [<xref ref-type="bibr" rid="scirp.123558-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.123558-ref14">14</xref>] . Brown et al. found that the mRNA and protein levels of NLRP3, ASC, and Caspase-1 were elevated in diabetic rats from the 4<sup>th</sup> or 8<sup>th</sup> week of diabetes [<xref ref-type="bibr" rid="scirp.123558-ref15">15</xref>] . Luo et al. indicated that the expression levels of NLRP3, ASC, and Caspase-1 proteins were significantly increased in the serum and adipose tissue of the patients with T2DM [<xref ref-type="bibr" rid="scirp.123558-ref16">16</xref>] . Our data suggested that the expression levels of NLRP3, ASC, and Caspase-1 were up-regulated not only in T2DM patients but also in PDM subjects. Moreover, the expression levels of NLRP3, ASC, and Caspase-1 were higher in the T2DM group when compared with those in the PDM group. Therefore, NLRP3 inflammasome complex is formed and activated in the patients with both T2DM and PDM.</p><p>The possible association with NLRP3 inflammasome and diabetes has been discussed previously [<xref ref-type="bibr" rid="scirp.123558-ref17">17</xref>] . Due to NLRP3 inflammasome could affect the blood glucose level and IR, which are related to the pathogenesis of diabetes [<xref ref-type="bibr" rid="scirp.123558-ref9">9</xref>] [<xref ref-type="bibr" rid="scirp.123558-ref17">17</xref>] , and facilitating diabetes-induced systemic chronic inflammation and insulin signaling [<xref ref-type="bibr" rid="scirp.123558-ref18">18</xref>] . Ruscitti et al. demonstrated that hyperglycemia will lead to the upregulation of NLRP3 [<xref ref-type="bibr" rid="scirp.123558-ref19">19</xref>] . Rheinheimer et al. have been suggested that IR is associated with increased NLRP3 expression in adipose tissue [<xref ref-type="bibr" rid="scirp.123558-ref9">9</xref>] . In this study, we found that NLRP3 inflammasome is positively correlated with blood glucose and IR-related indicators, and negatively correlated with HDL-C and HOMA-β, suggesting that NLRP3 may involve in IR and the development of diabetes by regulating glucose and lipid metabolism. Moreover, the blood glucose related indexes, FINs, and NLRP3 are crucial factors for IR. It is demonstrated that the increase of blood glucose level and activation of NLRP3 could lead to metabolic inflammation and IR. Therefore, the upregulation of NLRP3 in the serum of T2DM and PDM patients may contribute to the development of diabetes by regulating glucose and lipid metabolism, and IR. However, the sample size is small and the collection point is simple in this study.</p><p>Further studies are required to expand the sample size and collection range, and continue to explore the mechanism of NLRP3 inflammasome on glucose and lipid metabolism in the patients with T2DM and PDM. In addition, as the objects of study are T2DM and PDM, the expressions of inflammatory-related factors at different levels. It is suggested that it is more appropriate to study one kind of patients in the future. Finally, future studies need animal experiments to verify the relationship among NLRP3, glucolipid metabolism and IR.</p></sec><sec id="s5"><title>5. Conclusion</title><p>NLRP3 inflammasome participates in systemic chronic inflammation and insulin signaling. This study found that NLRP3 inflammasome is activated in patients with both T2DM and PDM and closely related to glucose and lipid metabolism, and IR. In addition, studies revealing the contribution of NLRP3 in IR signaling. This may offer potential novel therapeutic perspectives in T2DM prevention and treatment.</p></sec><sec id="s6"><title>Ethics Approval and Consent to Participate</title><p>This study was approved by the ethics committee of Yangtze University Health Science Center (YZLL2022-006) and participants provided written informed consent.</p></sec><sec id="s7"><title>Author Contributions</title><p>SJ and XW designed the study. SJ, Dang and XW drafted the manuscript. SJ, BQ and YT analyzed the data and filled the tables. XW and SJ revised the manuscript. All authors contributed to the article and approved the submitted version.<sup> </sup></p></sec><sec id="s8"><title>Funding</title><p>The Teaching Research Project of Yangtze University (JY2020042, JY2020128), The Central Government guides local funds for scientific and Technological Development (XZ202201YD0024C), Key R &amp; D Program of Hubei Province (2021BGD010), Hubei Province Scientific and Technological Research Project (D20201306), Hubei Medical Youth Tip-Top Talent (to XW Wang).</p></sec><sec id="s9"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest regarding the publication of this paper.</p></sec><sec id="s10"><title>Cite this paper</title><p>Hu, S.J., Liu, D., Zhang, Y.Q., Ding, Y.T., Li, B.Q. and Wang, X.W. (2023) NLRP3 Inflammasome in Relation to Glucose and Lipid Metabolism, and Insulin Resistance in Diabetes and Pre-Diabetes. Yangtze Medicine, 7, 1-10. https://doi.org/10.4236/ym.2023.71001</p></sec><sec id="s11"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.123558-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Saeedi, P., Petersohn, I., Salpea, P., et al. (2019) Global and Regional Diabetes Prevalence Estimates for 2019 and Projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9th Edition. Diabetes Research and Clinical Practice, 157, Article ID: 107843. https://doi.org/10.1016/j.diabres.2019.107843</mixed-citation></ref><ref id="scirp.123558-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Chinese Society of Endocrinology, Chinese Medical Association Diabetes Branch, Endocrinology and Metabolism Physician Branch of Chinese Medical Doctor Association, Endocrinology and Metabolism Branch of Chinese Research Hospital Association and Diabetes Branch of Chinese Research Hospital Association (2020) Expert Consensus on Adult Prediabetes Intervention in China. Chinese Journal of Endocrinology and Metabolism, 36, 371-380. (In Chinese) https://doi.org/10.3760/cma.j.cn311282-20200115-00022</mixed-citation></ref><ref id="scirp.123558-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Azemi, A.K., Mokhtar, S.S., Hou, L.J., Sharif, S.E.T. and Rasool, A.H.G. (2021) Model for Type 2 Diabetes Exhibits Changes in Vascular Function and Structure Due to Vascular Oxidative Stress and Inflammation. Biotechnic &amp; Histochemistry, 96, 498-506. https://doi.org/10.1080/10520295.2020.1823480</mixed-citation></ref><ref id="scirp.123558-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Jiang, H and Zhou, R.B. (2016) NLRP3 Inflammasome: A Novel Target for T2DM Treatment? Chinese Science Bulletin, 61, 3541-3547. (In Chinese)https://doi.org/10.1360/N972016-00653</mixed-citation></ref><ref id="scirp.123558-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hu, S., Hu, Y., Long, P., et al. (2022) The Effect of Tai Chi Intervention on NLRP3 and Its Related Antiviral Inflammatory Factors in the Serum of Patients with Pre-Diabetes. Frontiers in Immunology, 13, Article 1026509. https://doi.org/10.3389/fimmu.2022.1026509</mixed-citation></ref><ref id="scirp.123558-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Liang, F., Huang, T., Li, B., et al. (2020) High-Intensity Interval Training and Moderate-Intensity Continuous Training Alleviate β-Amyloid Deposition by Inhibiting NLRP3 Inflammasome Activation in APPswe/PS1dE9 Mice. NeuroReport, 31, 425-432. https://doi.org/10.1097/WNR.0000000000001429</mixed-citation></ref><ref id="scirp.123558-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wang, X., Yang, Y., Cai, W.-Q. and Lu, Y. (2020) The Relationship of Sphingosine Kinase 1 with Pyroptosis Provides a New Strategy for Tumor Therapy. Frontiers in Immunology, 11, Article 574990. https://doi.org/10.3389/fimmu.2020.574990</mixed-citation></ref><ref id="scirp.123558-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Unamuno, X., Gómez-Ambrosi, J., Ramírez, B., et al. (2021) NLRP3 Inflammasome Blockade Reduces Adipose Tissue Inflammation and Extracellular Matrix Remodeling. Cellular &amp; Molecular Immunology, 18, 1045-1057. https://doi.org/10.1038/s41423-019-0296-z</mixed-citation></ref><ref id="scirp.123558-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rheinheimer, J., De Souza, B.M., Cardoso, N.S., Bauer, A.C. and Crispim, D. (2017) Current Role of the NLRP3 Inflammasome on Obesity and Insulin Resistance: A Systematic Review. Metabolism, 74, 1-9. https://doi.org/10.1016/j.metabol.2017.06.002</mixed-citation></ref><ref id="scirp.123558-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Yang, N., Zhang, H.B. and Li, Y.X. (2019) Interpretation on the Update of American Diabetes Association Standards of Medical Care in Diabetes—2019. Medical Journal of Peking Union Medical College Hospital, 10, 476-480. (In Chinese)https://doi.org/10.3969/j.issn.1674-9081.2019.05.009</mixed-citation></ref><ref id="scirp.123558-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Matthews, D.R., Hosker, J.P., Rudenski, A.S., et al. (1985) Homeostasis Model Assessment: Insulin Resistance and β-Cell Function from Fasting Plasma Glucose and Insulin Concentrations in Man. Diabetologia, 28, 412-419. https://doi.org/10.1007/BF00280883</mixed-citation></ref><ref id="scirp.123558-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wang, Y., Zhong, J., Zhang, X., et al. (2016) The Role of HMGB1 in the Pathogenesis of Type 2 Diabetes. Journal of Diabetes Research, 2016, Article ID: 2543268. https://doi.org/10.1155/2016/2543268</mixed-citation></ref><ref id="scirp.123558-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Zhu, Z.G., Yang, H.Y., Huang, L., et al. (2021) The Correlation of Serum MicroRNA-152 Expression with Lipid Metabolism and Insulin Resistance in Patients with Diabetes Mellitus. China Journal of Modern Medicine, 31, 1-6. (In Chinese)https://doi.org/10.3969/j.issn.1005-8982.2021.08.001</mixed-citation></ref><ref id="scirp.123558-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Hu, S., Wan, X., Li, X. and Wang, X. (2022) Aerobic Exercise Alleviates Pyroptosis-Related Diseases by Regulating NLRP3 Inflammasome. Frontiers in Physiology, 13, Article 965366. https://doi.org/10.3389/fphys.2022.965366</mixed-citation></ref><ref id="scirp.123558-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Brown, E.C., Franklin, B.A., Regensteiner, J.G. and Stewart, K.J. (2020) Effects of Single Bout Resistance Exercise on Glucose Levels, Insulin Action, and Cardiovascular Risk in Type 2 Diabetes: A Narrative Review. Journal of Diabetes and Its Complications, 34, Article ID: 107610. https://doi.org/10.1016/j.jdiacomp.2020.107610</mixed-citation></ref><ref id="scirp.123558-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Luo, B., Li, B., Wang, W., et al. (2014) NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model. PLOS ONE, 9, e104771. https://doi.org/10.1371/journal.pone.0104771</mixed-citation></ref><ref id="scirp.123558-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Gora, I.M., Ciechanowska, A. and Ladyzynski, P. (2021) NLRP3 Inflammasome at the Interface of Inflammation, Endothelial Dysfunction, and Type 2 Diabetes. Cells, 10, Article No. 314. https://doi.org/10.3390/cells10020314</mixed-citation></ref><ref id="scirp.123558-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Sepehri, Z., Kiani, Z., Afshari, M., et al. (2017) Inflammasomes and Type 2 Diabetes: An Updated Systematic Review. Immunology Letters, 192, 97-103. https://doi.org/10.1016/j.imlet.2017.10.010</mixed-citation></ref><ref id="scirp.123558-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Ruscitti, P., Cipriani, P., Di Benedetto, P., et al. (2015) Monocytes from Patients with Rheumatoid Arthritis and Type 2 Diabetes Mellitus Display an Increased Production of Interleukin (IL)-1β via the Nucleotide-Binding Domain and Leucine-Rich Repeat Containing Family Pyrin 3(NLRP3)-Inflammasome Activation: A Possible Implication for Therapeutic Decision in These Patients. Clinical and Experimental Immunology, 182, 35-44. https://doi.org/10.1111/cei.12667</mixed-citation></ref></ref-list></back></article>